Abstract

Multiple factors influence the survival of disseminated breast tumour cells (DTCs) in bone. Whilst gene signature studies have identified genes that predict a propensity of tumours to metastasise to bone, the bone environment is key in determining the fate of these tumour cells. Breast cancer cells locate to specific niches within the bone that support their survival, regulated by host factors within the bone microenvironment including bone cells, cells of the bone micro vasculature, immune cells and the extracellular matrix. Reproductive endocrine hormones affect bone and clinical studies across the menopausal transition have provided comprehensive understanding of the changes in the bone microenvironment during this time. Menopause is characterised by a decrease in ovarian oestradiol and inhibins, with an increase in pituitary follicle stimulating hormone and this review will focus on the role of these 3 hormones in determining the fate of DTCs in bone. Both in vivo and clinical data suggest premenopausal bone is a conducive environment for growth of breast cancer cells in bone. Adjuvant cancer treatment aims to reduce the risk of tumour recurrence by targeting DTCs and drugs targeting the bone resorbing osteoclasts, such as bisphosphonates, have been evaluated in this setting. Both preclinical and adjuvant clinical studies and have shown that bisphosphonates ability to decrease tumour growth in bone is influenced by levels of endocrine hormones, with enhanced effects in a postmenopausal bone microenvironment. The challenge is to understand the molecular mechanisms behind this phenomenon and to evaluate if alternative adjuvant bone targeted therapies may be effective in premenopausal women.